Mitsubishi UFJ Trust & Banking Corp Has $23.67 Million Stock Position in Hologic, Inc. $HOLX

Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 363,316 shares of the medical equipment provider’s stock after purchasing an additional 10,106 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.16% of Hologic worth $23,674,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of HOLX. Greenleaf Trust raised its stake in shares of Hologic by 5.1% during the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock worth $233,000 after buying an additional 173 shares during the last quarter. Allworth Financial LP boosted its position in shares of Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the last quarter. Savant Capital LLC boosted its position in shares of Hologic by 1.2% in the 2nd quarter. Savant Capital LLC now owns 19,606 shares of the medical equipment provider’s stock worth $1,278,000 after purchasing an additional 232 shares during the last quarter. First American Bank grew its stake in shares of Hologic by 0.9% during the second quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock worth $1,870,000 after purchasing an additional 245 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its holdings in Hologic by 1.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 14,788 shares of the medical equipment provider’s stock valued at $964,000 after purchasing an additional 246 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

HOLX stock opened at $74.15 on Friday. The stock has a 50-day moving average price of $69.76 and a two-hundred day moving average price of $65.68. The stock has a market cap of $16.49 billion, a PE ratio of 30.77, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $80.31.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.01 earnings per share. Equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In other news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the sale, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.88% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. JPMorgan Chase & Co. restated a “neutral” rating and set a $78.00 price objective on shares of Hologic in a report on Wednesday, October 22nd. BTIG Research restated a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Leerink Partners lifted their target price on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a report on Tuesday, October 21st. Finally, Morgan Stanley boosted their target price on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $79.77.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.